FDA's Complete Response Letter for Relfydess cited only manufacturing and analytical observations, no safety or efficacy issues. Still not FDA-approved in the US.
The FDA issued a Complete Response Letter for Galderma's Relfydess (RelabotulinumtoxinA), a ready-to-use liquid neurotoxin. The letter cited only manufacturing-site inspection observations and analytical-method optimization, with no safety or efficacy deficiencies. Relfydess is approved in 33 markets worldwide but remains not FDA-approved in the United States.
On July 1, 2026, Galderma disclosed that the US Food and Drug Administration had issued a Complete Response Letter (CRL) for RelabotulinumtoxinA, the ready-to-use liquid neuromodulator sold outside the US under the brand name Relfydess. A CRL is the FDA's formal notice that it will not approve an application in its current form. Notably, the agency flagged only manufacturing and analytical-method items. The clinical safety and efficacy portions of the application were not questioned. Relfydess remains not FDA-approved in the United States.
The FDA's letter cited observations made during a manufacturing-site inspection and the need for analytical-method optimization. Galderma stated that all other aspects of the Biologics License Application, including the safety-related and efficacy-related parts, did not solicit deficiencies to be addressed. In plain terms, the regulator did not raise concerns about whether the product works or whether it is safe. The hold-up is with factory processes and testing methods.
This marks the second Complete Response Letter for the product in three years. An earlier 2023 letter had cited chemistry, manufacturing, and controls issues rather than clinical ones. Galderma says it is putting corrective and preventive actions in place and will seek further guidance through continued dialogue with the FDA. Until those observations are resolved, RelabotulinumtoxinA cannot be legally marketed or sold in the United States.
Relfydess is described by Galderma as the first and only ready-to-use liquid neuromodulator, built with its PEARL technology and requiring no reconstitution from a powder. That formulation is the main way it differs from neurotoxins already cleared in the US, such as onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), prabotulinumtoxinA (Jeuveau), and daxibotulinumtoxinA (Daxxify), all of which are FDA-approved and are supplied as powders that a provider mixes before injection.
Globally, Relfydess is approved in 33 markets and has launched in more than 20, including Europe, the United Kingdom, the Middle East, Asia, and Australia. For consumers in the United States, however, nothing changes at the clinic: the product is not available and not FDA-approved here. Because the letter is limited to manufacturing and analytical items, it does not signal a clinical problem with the toxin itself.
Galderma is seeking US approval of RelabotulinumtoxinA for two aesthetic uses: temporary improvement of glabellar lines (frown lines) and lateral canthal lines (crow's feet) in adults. Its READY Phase III program included four studies with more than 1,900 participants. The company has not given a public timeline for when a resubmission might be accepted or when a decision could follow.
Readers should treat any US offer of Relfydess as a red flag until the FDA grants approval, since the product is not legally available in the United States. This report explains a regulatory event and is not medical advice; it does not recommend starting, stopping, or switching any treatment. Anyone weighing a wrinkle-relaxing injection should discuss FDA-approved options with a licensed, verified provider.